Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Article 15 (5) (k)-(l): Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
gxplex>GxPlexBot Import from GxPlex Excel |
||
| Line 10: | Line 10: | ||
}} | }} | ||
{{:Document:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004}} | {{:Document:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004}} | ||
{| class="gplx-infobox" | |||
{| class=" | |||
|- | |- | ||
! | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Scope | |||
| HM | | HM | ||
|- | |- | ||
! | ! Document part | ||
| Article 15 | | Article 15 | ||
(5) (k)-(l) | (5) (k)-(l) | ||
|- | |- | ||
! | ! Language | ||
| EN | | EN | ||
|- | |- | ||
! | ! Original entry by | ||
| Florian Adragna | | Florian Adragna | ||
|- | |- | ||
! | ! Contributors | ||
| Β | | Β | ||
|- | |- | ||
! | ! Tags (EN) | ||
| Β | | Β | ||
|- | |- | ||
! | ! Tags (original language) | ||
| Β | | Β | ||
|- | |- | ||
! | ! Tags (FR) | ||
| Β | | Β | ||
|- | |- | ||
! | ! Comment | ||
| Ethics committee considerations for subject safety and rights | | Ethics committee considerations for subject safety and rights | ||
|} | |} | ||
== | == Content == | ||
Ethics committee opinion | Ethics committee opinion | ||
15.β [...] Β | 15.β [...] Β | ||
Revision as of 14:27, 29 June 2026
| Document information | |
|---|---|
| Reference | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| Validity area | GBR |
| Scope(s) | HM |
| Document name | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Version / Revision | 01-May-2004 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Scope | HM |
| Document part | Article 15
(5) (k)-(l) |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags (EN) | |
| Tags (original language) | |
| Tags (FR) | |
| Comment | Ethics committee considerations for subject safety and rights |
Content
Ethics committee opinion 15.β [...] (5) In preparing its opinion, the committee shall consider, in particular, the following mattersβ (k)the amounts, and, where appropriate, the arrangements, for rewarding or compensating investigators and subjects; (l)the terms of any agreement between the sponsor and the owner or occupier of the trial site which are relevant to the arrangements referred to in sub-paragraph (k)
